Lymphoma Research Foundation and Follicular Lymphoma Innovation (IFLI) announce major investment to host 2026 International Scientific Workshop to advance research and innovation in follicular ...

Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a malignancy where the first-generation drug ibrutinib (Imbruvica ...

For people dealing with cancer, that’s an added stressor that can tip things right over the edge. When I was first diagnosed with follicular lymphoma, a chronic and incurable — but very treatable form ...

In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not. When I started receiving treatment ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.